References
- American Diabetes Association. Standards of medical care for patients with diabetes mellitus (Position Statement). Diabetes Care 28 (suppl 1), s4–s36, 2005.10.2337/diacare.28.suppl_1.S4
- Baron AD, Brechtel G. Insulin differentially regulates systemic and skeletal muscle vascular resistance. Am J Physiol 265, E61–E67, 1993.10.1152/ajpendo.1993.265.1.E618338155
- Bollenbach A, Schutte AE, Kruger R, Tsikas D. An ethnic comparison of arginine dimethylation and cardiometabolic factors in healthy black and white youth: The ASOS and African-PREDICT Studies. J Clin Med 9, 844, 2020.10.3390/jcm9030844714131732244968
- Celik M, Cerrah S, Arabul M, Akalin A. Relation of asymmetric dimethylarginine levels to macrovascular disease and inflammation markers in type 2 diabetic patients. J Diabetes Res 2014, 139215, 2014.10.1155/2014/139215399688524804267
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18, 499–502, 1972.10.1093/clinchem/18.6.499
- Ganz T, Wainstein J, Gilad S, Limor R, Boaz M, Stern N. Serum asymmetric dimethylarginine and arginine levels predict microvascular and macrovascular complications in type 2 diabetes mellitus. Diabetes Metab Res Rev 33, 2017.10.1002/dmrr.283627393712
- Ghule A, Kamble TK, Talwar D, Kumar S, Acharya S, Wanjari A, Gaidhane SA, Agrawal S. Association of serum high sensitivity C-reactive protein with pre-diabetes in rural population: A two-year cross-sectional study. Cureus 13, e19088, 2021.10.7759/cureus.19088862671034868746
- Groos S, Kretschmann J, Macare C, Weber A, Hagen B. Quality assurance report 2016 disease-management-programmes in North Rhine, 2017. Available at https://www.kvno.de/downloads/quali/qualbe_dmp16.pdf. Accessed 23 Jun 2022.
- Hisalkar PJ, Shekhar PB, Bidwe SE, Kamble CG, Nemade ST, Powar JD, Patne A. Asymmetrical dimethylarginine (ADMA), an endothelial dysfunctional biomarker for type 2 diabetes mellitus, the meta analysis. Ind J Bas Appl Med Res 6, 496–506, 2017.
- Hsu CP, Hsu PF, Chung MY, Lin SJ, Lu TM. Asymmetric dimethylarginine and long-term adverse cardiovascular events in patients with type 2 diabetes: relation with the glycemic control. Cardiovasc Diabetol 13, 156, 2014.10.1186/s12933-014-0156-1426214425467091
- Jawalekar SL, Karnik A, Bhutey A. Risk of cardiovascular diseases in diabetes mellitus and serum concentration of asymmetrical dimethylarginine. Biochem Res Int 2013, 189430, 2013.10.1155/2013/189430380427724187621
- Kanmani S, Kwon M, Shin MK, Kim MK. Association of C-reactive protein with risk of developing type 2 diabetes mellitus, and role of obesity and hypertension: A large population-based Korean cohort study. Sci Rep 9, 4573, 2019.10.1038/s41598-019-40987-8641810230872696
- Kelley-Hedgepeth A, Lloyd-Jones DM, Colvin A, Matthews KA, Johnston J, Sowers MR, Sternfeld B, Pasternak RC, Chae CU; SWAN Investigators. Ethnic differences in C-reactive protein concentrations. Clin Chem 54, 1027–1037, 2008.10.1373/clinchem.2007.09899618403563
- Krzyzanowska K, Mittermayer F, Krugluger W, Schnack C, Hofer M, Wolzt M, Schernthaner G. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes. Atherosclerosis 189, 236–240, 2006.10.1016/j.atherosclerosis.2005.12.00716414052
- Kuniss N, Freyer M, Muller N, Kielstein V, Muller UA. Expectations and fear of diabetes-related long-term complications in people with type 2 diabetes at primary care level. Acta Diabetol 56, 33–38, 2019.10.1007/s00592-018-1217-930159745
- Liu C, Feng X, Li Q, Wang Y, Li Q, Hua M. Adiponectin, TNF-α and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis. Cytokine 86, 100–109, 2016.10.1016/j.cyto.2016.06.02827498215
- Matthews KA, Sowers MF, Derby CA, Stein E, Miracle-McMahill H, Crawford SL, Pasternak RC. Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women’s Health Across the Nation (SWAN). Am Heart J 149, 1066–1073, 2005.10.1016/j.ahj.2004.08.02715976790
- Nazmi A, Victora CG. Socioeconomic and racial/ethnic differentials of C-reactive protein levels: a systematic review of population-based studies. BMC Public Health 7, 212, 2007.10.1186/1471-2458-7-212201871917705867
- Pan A, Wang Y, Yuan JM, Koh WP. High-sensitive C-reactive protein and risk of incident type 2 diabetes: a case-control study nested within the Singapore Chinese Health Study. BMC Endocr Disord 17, 8, 2017.10.1186/s12902-017-0159-5529977728178951
- Paiva H, Lehtimaki T, Laakso J, Ruokonen I, Rantalaiho V, Wirta O, Pasternack A, Laaksonen R. Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism 52, 303–307, 2003.10.1053/meta.2003.5004812647267
- Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G, Nishigaki I. The vascular endothelium and human diseases. Int J Biol Sci 9, 1057–1069, 2013.10.7150/ijbs.7502383111924250251
- Sciacqua A, Grillo N, Quero M, Sesti G, Perticone F. Asymmetric dimethylarginine plasma levels and endothelial function in newly diagnosed type 2 diabetic patients. Int J Mol Sci 13, 13804–13815, 2012.10.3390/ijms131113804350955123203035
- Schutte AE, Schutte R, Huisman HW, van Rooyen JM, Fourie CM, Malan L, Malan NT, Schwedhelm E, Strimbeanu S, Anderssohn M, Boger RH. Dimethylarginines: their vascular and metabolic roles in Africans and Caucasians. Eur J Endocrinol 162, 525–533, 2010.10.1530/EJE-09-086519996198
- Shi Y, Vanhoutte PM. Macro- and microvascular endothelial dysfunction in diabetes. J Diabetes 9, 434–449, 2017.10.1111/1753-0407.1252128044409
- Sydow K, Fortmann SP, Fair JM, Varady A, Hlatky MA, Go AS, Iribarren C, Tsao PS; ADVANCE Investigators. Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities. Clin Chem 56, 111–120, 2010.10.1373/clinchem.2009.13620019892843
- Tsikas D, Bollenbach A, Hanff E, Kayacelebi AA. Asymmetric dimethylarginine (ADMA), symmetric dimethylargi-nine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes. Cardiovasc Diabetol 17, 1, 2018.10.1186/s12933-017-0656-x575349229301528
- Wang X, Bao W, Liu J, Ouyang YY, Wang D, Rong S, Xiao X, Shan ZL, Zhang Y, Yao P, Liu LG. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 36, 166–175, 2013.10.2337/dc12-0702352624923264288
- Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: New challenges of the old problem. Arch Intern Med 164, 2126–2134, 2004.10.1001/archinte.164.19.212615505126
- Wieczor R, Wieczor AM, Kulwas A, Rosc D. ADMA (asymmetric dimethylarginine) and angiogenic potential in patients with type 2 diabetes and prediabetes. Exp Biol Med 246, 153–162, 2021.10.1177/1535370220959738787112132957808
- Xiong Y, Lei M, Fu S, Fu Y. Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes. Life Sci 77, 149–159, 2005.10.1016/j.lfs.2004.10.06215862600
- Zaciragic A, Hasanefendic B, Avdagic N, Lepara O, Babic N, Huskic J, Mulabegovic N. Gender comparison of serum asymmetric dimethylarhinine and C-reactive protein concentration in patients with diabetes mellitus type 2. Medical Journal 20, 85–90, 2014.